Conventional Antiarrhythmics Class I–IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias [PDF]
PharmaceuticalsThis review examines and hypothesizes cytoprotection as a conceptual therapeutic criterion for antiarrhythmic drugs, referring to the possibility of suppressing arrhythmias while avoiding adverse electrophysiological or systemic effects.
Lozic Marin +2 more
exaly +5 more sources
Pediatric antiarrhythmics and toxicity: A clinical review
Journal of the American College of Emergency Physicians OpenAntiarrhythmic medications are fundamental in the acute and chronic management of pediatric arrhythmias. Particularly in the pediatric patient population, associated antiarrhythmic toxicities represent important potential adverse effects.
Robert Przybylski +2 more
exaly +2 more sources
An Updated Systematic Review and Meta-Analysis of the Efficacy and Safety of Catheter Ablation in Comparison to Antiarrhythmic Drugs for Managing Atrial Fibrillation [PDF]
Advanced Biomedical ResearchThis meta-analysis compares the efficacy and safety of catheter ablation with antiarrhythmic therapy for atrial fibrillation (AF) in randomized controlled trials (RCTs) We systematically searched PubMed, Web of Science, Google Scholar, Embase, and ...
Ketan Garg +7 more
doaj +2 more sources
Repositioning of antiarrhythmics for prostate cancer treatment: a novel strategy to reprogram cancer-associated fibroblasts towards a tumor-suppressive phenotype [PDF]
Journal of Experimental & Clinical Cancer ResearchBackground Cancer-associated fibroblasts (CAFs) play a significant role in fueling prostate cancer (PCa) progression by interacting with tumor cells. A previous gene expression analysis revealed that CAFs up-regulate genes coding for voltage-gated cation
Valentina Doldi +8 more
doaj +2 more sources
Drugs acting on the heart: antiarrhythmics
, 2018 Arrhythmias are abnormalities of cardiac rate or rhythm occurring for a variety of reasons. They are common in the perioperative period and in intensive care. Causes may reflect an underlying heritable predisposition, the presence of new pathology either
C Hebbes (7739255) +1 more
core +8 more sources
Сardioprotective agents with biaromatic structure. Part 2. HCN channel blockers
Фармакокинетика и Фармакодинамика, 2022 Hyperpolarization-activated cyclic nucleotide–gated (HCN) channels, primarily their HCN4 subtype, are one of the promising targets for the development of cardioprotective agents.
G. V. Mokrov
doaj +1 more source
Фармакокинетика и Фармакодинамика, 2023 The hERG subtype potassium channel (Kv11.1) is one of the most important and one of the most studied biological targets for the creation of cardioprotective agents.
G. V. Mokrov
doaj +1 more source
Prenatally diagnosed fetal heart rhythm abnormalities—incidence, diagnosis and outcome
Clinical and Experimental Obstetrics & Gynecology, 2022 Backrounds: Fetal arrhythmias represent a significant cause of fetal morbidity and mortality and occur in approximately 1–3% of pregnancies. The unknown fetal arrhythmias are the cause of intrauterine fetal demise in as many as 3–10% of cases, as well as
Jelena Stamenković +7 more
doaj +1 more source
Сardioprotective agents with biaromatic structure. Part 1. Calcium channel blockers
Фармакокинетика и Фармакодинамика, 2022 Cardiovascular diseases (CVD) are widespread and the leading cause of morbidity and mortality worldwide. Drugs for the treatment of CVD have been developed since the beginning of the 20th century.
G. V. Mokrov
doaj +1 more source
Сardioprotective agents with biaromatic structure. Part 6. Beta blockers
Фармакокинетика и Фармакодинамика, 2023 β-Blockers are one of the oldest classes of cardioprotectors used in the treatment of cardiovascular diseases. They reduce the heart rate, have a hypotensive effect, inhibit myocardial contractility and have antiarrhythmic properties.
G. V. Mokrov
doaj +1 more source